Methods and devices for delivering GLP-1 and uses thereof
View Patent ↗The invention provides various devices for delivering Glucagon-Like Peptide-1 (7-36), in various infusion patterns and rates, to optimally stimulate carbohydrate metabolism, to inhibit gastropancreatic secretion and gastric motility, and to treat various disease conditions (including diabete) as described in the instant specification. The devices and methods of the invention provide various ways to deliver doses (escalating, constant, on demand, etc.) of GLP-1 in response to different patient need.
1. A device for delivering an effective amount of a GLP-1 compound to a patient in need of GLP-1 receptor stimulation comprising:
(a) a fluid storage chamber containing a GLP-1 compound, said fluid storage chamber having an output orifice through which said GLP-1 compound can be expelled;
(b) a pump chamber functionally connected to said fluid storage chamber by a moveable barrier, wherein the rate of movement of said moveable barrier caused by said pump chamber is adjustable to produce variable dosing under patient control;
(c) a hydraulic fluid reservoir functionally connected to a first actuator and having a high viscosity fluid stored therein, said hydraulic fluid reservoir fluidly connected to said pump chamber by a fixed aperture; and
(d) a second actuator which physically acts on said pump chamber, wherein said second actuator is controlled independently of said first actuator;
wherein said pump chamber continuously expands upon actuation of said device with said first actuator;
wherein operating said first actuator causes said high viscosity fluid to flow into said pump chamber through said fixed aperture at a constant rate, thereby displacing said moveable barrier to compress said fluid storage chamber and causing a quantity of said GLP-1 compound to be expelled through said orifice;
wherein operating said second actuator independently causes displacement of said moveable barrier to compress said fluid storage chamber, thereby causing a quantity of said GLP-1 compound to be expelled; and
wherein concurrently operating both of said first and second actuators causes displacement of the moveable barrier to compress said fluid storage chamber at an increased rate relative to operating either actuator alone.
2. The device of claim 1 , wherein said GLP-1 compound is GLP-1.
3. The device of claim 1 , wherein said GLP-1 compound is a GLP-1 analog with substantially the same or better potency than that of GLP-1.
4. The device of claim 1 , wherein said GLP-1 compound is a derivative of GLP-1 or GLP-1 analog, each of which has substantially the same or better potency than that of GLP-1.
5. The device of claim 1 , further comprising a needle functionally connected to the output orifice for delivery of GLP-1 compound expelled from said fluid storage chamber to an individual.
6. The device of claim 1 , wherein said first actuator comprises two or more springs.
7. The device of claim 1 , wherein said second actuator comprises two or more springs.
8. The device of claim 1 , wherein the viscosity of said high viscosity fluid is about ISO VG 1500 or more.
9. The device of claim 1 , wherein said first actuator causes constant delivery of said GLP-1 compound, and said second actuator causes a bolus delivery of said GLP-1 compound under patient control.
10. The device of claim 1 , wherein said first actuator generates a force of from about 0.001 lbs to about 10 lbs.
11. A method of stimulating a GLP-1 receptor in a subject in need of such stimulation, said method comprising the step of administering to a patient an effective amount of a GLP-1 compound using a device comprising:
(a) a fluid storage chamber containing a GLP-1 compound, said fluid storage chamber having an output orifice through which said GLP-1 can be expelled;
(b) a pump chamber functionally connected to said fluid storage chamber by a moveable barrier, wherein the rate of movement of said moveable barrier caused by said pump chamber is adjustable to produce variable dosing under patient control;
(c) a hydraulic fluid reservoir functionally connected to a first actuator and having a high viscosity fluid stored therein, said hydraulic fluid reservoir fluidly connected to said pump chamber by a fixed aperture; and
(d) a second actuator which physically acts on said pump chamber, wherein said second actuator is controlled independently of said first actuator;
wherein said pump chamber continuously expands upon actuation of said device with said first actuator;
wherein operating said first actuator causes said high viscosity fluid to flow into said pump chamber through said fixed aperture at a constant rate, thereby displacing said moveable barrier to compress said fluid storage chamber and causing a quantity of said GLP-1 compound to be expelled through said orifice;
wherein operating said second actuator independently causes displacement of said moveable barrier to compress said fluid storage chamber, thereby causing a quantity of said GLP-1 compound to be expelled; and
wherein concurrently operating both of said first and second actuators causes displacement of the moveable barrier to compress said fluid storage chamber at an increased rate relative to operating either actuator alone.
12. The method of claim 11 , wherein said GLP-1 compound is GLP-1.
13. The method of claim 11 , wherein said GLP-1 compound is a GLP-1 analog with substantially the same or better potency than that of GLP-1.
14. The method of claim 11 , wherein said GLP-1 compound is a derivative of GLP-1 or GLP-1 analog, each of which has substantially the same or better potency than that of GLP-1.
15. The method of claim 11 , wherein said GLP-1 compound is delivered continuously.
16. The method of claim 15 , wherein the rate of delivery is equivalent to about 0.25 to 6 pmol/kg body weight/min, preferably from about 0.5 to about 1.2 pmol/kg/min, or from about 0.6 to about 2.4 pmol/kg/min of GLP-1.
17. The method of claim 15 , wherein the entire delivery period for said GLP-1 compound is about 6 hrs, about 12 hrs, about 1 day, about 3 days, about 5 days, about 2 weeks, about 1 month, about 3 months, about 6 months, about 1 year or more.
18. The method of claim 11 , wherein said GLP-1 compound is delivered intermittently.
19. The method of claim 18 , wherein the rate of delivery, as averaged over the entire delivery period, is equivalent to about 0.25 to 6 pmol/kg body weight/min, preferably from about 0.5 to about 1.2 pmol/kg/min, or from about 0.6 to about 2.4 pmol/kg/min of GLP-1.
20. The method of claim 18 , wherein the entire deliver period for said GLP-1 compound is about 6 hrs, about 12 hrs, about 1 day, about 3 days, about 5 days, about 2 weeks, about 1 month, about 3 months, about 6 months, about 1 year or more.
21. The method of claim 11 , further comprising a needle functionally connected to the output orifice for delivery of GLP-1 compound expelled from said fluid storage chamber to an individual.
22. The method of claim 11 , wherein said first actuator comprises two or more springs.
23. The method of claim 11 , wherein said second actuator comprises two or more springs.
24. The method of claim 11 , wherein the viscosity of said high viscosity fluid is about ISO VG 1500 or more.
25. The method of claim 11 , wherein said first actuator causes constant delivery of said GLP-1 compound, and said second actuator causes a bolus delivery of said GLP-1 compound under patient control.
26. The method of claim 11 , wherein said first actuator generates a force of from about 0.001 lbs to about 10 lbs.